1. Introduction {#s1}
===============

Dyslipidemia is well-documented as a major risk factor for coronary artery disease (CAD) to be closely associated with the progression of coronary atherosclerosis and the stability of coronary artery plaques. A lot of studies have demonstrated that elevated low-density lipoprotein cholesterol (LDL-C) level, in particular, plays a causal role in atherogenesis.[@b1] Recently, non-high density lipoprotein cholesterol (non-HDL-C) has also been emerged as a promising risk predictor particularly among hypertriglyceridemic individuals.[@b1] Moreover, apolipoproteins B (apoB), the major structural protein of non-HDL particles, is recognized as even a better risk predictor than LDL-C for CAD.[@b1] Interestingly, investigators also have paid attention to the usefulness of lipid and lipoprotein ratios in predicting the presence and the prognosis of CAD. Among them, total cholesterol to HDL-C ratio (TC/HDL-C), LDL-C/HDL-C and apoB/apoA-I are found to be the most commonly used ratios,[@b2]--[@b5] but whether they are stronger predictors for the severity of CAD compared with the traditional lipid and lipoprotein parameters remain under discussion.

Diabetes mellitus (DM) is an independent risk factor for the development and mortality of CAD.[@b6] The presence of DM portends an adverse cardiovascular prognosis with a 2- to 3-fold higher compared with nondiabetic people.[@b6] Of note, the lipid and lipoprotein profile in patients with type 2 DM is different from the general population, and the former is characterized by a high triglyceride (TG) level and a low HDL-C level.[@b7],[@b8] Although lipoprotein ratios can serve as markers of insulin resistance, whether a high TG or a low HDL-C relates to the relationship of DM to CAD progression is still controversial. To our best knowledge, little study has performed on the correlation between the lipid and lipoprotein ratios and the severity of CAD in type 2 DM (T2DM) patients. Much less data is available on the correlation using a strict assessment like Gensini score (GS) for CAD severity in DM patients, especially in patients with new on-set CAD and T2DM. Indeed, our previous study revealed that apoB/apoA-I ratio was associated with GS in stable CAD patients with T2DM and the association did not persist after adjustments for some CAD risk factors.[@b9] However, in our previous study, the participants were patients with stable CAD, but the ones with prior revascularization were included. The data are not available to date concerning the association between lipid and lipoprotein ratio and CAD severity in patients with T2DM and new on-set CAD.

The present study, therefore, aimed to explore the usefulness of the lipid and lipoprotein ratios of currently commonly used including TG/HDL-C, TC/HDL-C, LDL-C/HDL-C, TG/apoA-I, LDL-C/apoA-I, non-HDL-C/apoA-I and apoB/apoA-I in predicting the severity of new on-set CAD assessed by GS in patients with T2DM.

2. Methods {#s2}
==========

2.1. Study population {#s2a}
---------------------

All patients in the study have been reviewed by the appropriate ethics committee and have therefore been performed in accordance with the ethical standards as our previous studies.[@b10]--[@b12]

From a group of type 2 DM patients who were referred for elective coronary angiography due to angina-like chest pain and/or positive treadmill exercise test or clinically indicated coronary CT angiography in the Division of Dyslipidemia of Fu Wai Hospital (Beijing, China), 380 were newly angiography-proven onset CAD patients and referral for the present study. Patients with pre-percutaneous coronary intervention (Pre-PCI, *n* = 245), pre-coronary artery bypass grafting (pre-CABG, *n* = 21), post-myocardial infarction (MI) but did not underwent revascularization (*n* = 144), had an abnormal baseline cardiac troponin I (cTnI, *n* = 61) level and/or valvular heart disease (*n* = 7) were excluded. Patients with heart failure were not included in the present study, and all patients in this study were with a left ventricular ejection fraction (LVEF) \> 50%. Clinical characteristics, lipid parameters and laboratory test information of the study patients were collected. Lipid ratios were calculated and recorded. The definitions of hypertension, DM, and dyslipidemia were reported in our previous studies.[@b10]--[@b12]

2.2. Laboratory tests {#s2b}
---------------------

Baseline laboratory data measurements were conducted by the Clinical Chemistry Department of Fu Wai hospital. Blood samples were obtained for all patients from the cubital vein after a 12-h overnight fast before coronary angiography. TC and TG were measured by enzymatic method and HDL-C by a direct method (Roche Diagnostics, Basel, Switzerland). LDL-C was obtained by Friedewald\'s formula (if fasting triglycerides \< 3.39 mmol/L) or by ultracentrifugation. ApoB and apoA-I were measured by an immunoturbidimetric method (Tina-quant, Roche Diagnostics) calibrated against the World Health Organization/International Federation of Clinical Chemistry reference standard SP3-07 as our previous study.[@b13] Lipid and lipoprotein ratios and non-HDL-C were calculated directly. The levels of high- sensitive C-reactive protein (hs-CRP) were measured using immunoturbidometry (Beckmann Assay 360, Bera, Calif, USA) as we previously reported.[@b14] All other including biomarkers were analyzed by standard hematological and biochemical tests. LVEF was accessed by biplane Simpson\'s method. The endocardial border was manually traced in the apical four-chamber and two-chamber views in end-diastole and end-systole. Left ventricular enddiastolic volume (LVEDV), left ventricular endsystolic volume (LVESV), and LVEF were assessed.

2.3. Angiographic examination {#s2c}
-----------------------------

Coronary angiographic examination and the severity of CAD assessment using GS assessment system[@b15],[@b16] had been reported in our previous studies.[@b10]--[@b12]

Based on the tertiles of GS, the enrolled patients were classified into the three groups (low GS ≤ 24-point, *n* = 127; intermediate GS 24--47 points, *n* = 124; high GS ≥ 47-point, *n* = 129).

2.4. Statistical analysis {#s2d}
-------------------------

Data were showed as mean ± SD or median (Q1--Q3 quartiles) for continuous variables and number (percentage) for categorical variables. Independent sample *t*-test, Mann-- Whitney *U*-test, and *χ*^2^-tests were performed where appropriate to examine the difference of variables between groups.

In order to identify the factors that were independently associated with high GS (over than 47-point), binary univariate and multiple logistic regression using forward stepwise selection process were performed. Variables for which in univariate logistic regression analysis with *P* \< 0.05 were subsequently included in multivariate logistic regression analysis model. Correlations between two variables were examined using Spearman or Pearson\'s correlation analysis when appropriate. Receiver operating characteristic (ROC) curve analysis was constructed at the most discriminating cut-off value aimed to document the predictive power of the lipid ratio for high GS. A two-sided *P* \< 0.05 was considered statistically significant.

The statistical analyses were performed using SPSS version19.0 software (Chicago, Illinois, USA) as our previous studies.[@b10]--[@b12]

3. Results {#s3}
==========

3.1. Baseline characteristics {#s3a}
-----------------------------

The study population consisted of 258 men (67.9%) and 122 women (32.1%), aged 37--82 (mean: 59.9 ± 9.3) years. All patients were diagnosed with CAD accompanying with type 2 DM.

Patients were grouped according to the tertiles of GS (low GS group, *n* = 127, 33.4%; intermediate GS group, *n* = 124, 32.6%; high GS group, *n* = 129, 33.9%) and the baseline characteristics were summarized in [Table 1](#jgc-13-08-685-t01){ref-type="table"}. The GS ranged from 4-point to 194-point with median 32 point (18.8--56.5 point), In brief, patients with higher GS were often accompanied with higher levels of the atherogenic lipid and lipoprotein profile including LDL-C, non-HDL-C, lipoprotein (A), and apoB (all *P* \< 0.05, [Table 1](#jgc-13-08-685-t01){ref-type="table"}), and higher lipid and lipoprotein ratios including LDL-C/HDL-C, LDL-C/apoA-I, non-HDL-C/apoA-I, and apoB/apoA-I (all *P* \< 0.05, [Table 1](#jgc-13-08-685-t01){ref-type="table"}).

3.2. Logistic regression analysis {#s3b}
---------------------------------

Logistic regression analysis was used for detecting the independent predictors for high GS (\> 47-point). According to the consequence of the univariate regression analysis, which was performed firstly (data not shown), The significant parameters with *P* \< 0.05 including LDL-C, non-HDL-C, apoB, and lipoprotein (A), the ratios of TC/HDL-C, LDL-C/HDL-C, non-HDL-C/HDL-C, apoB/HDL-C, LDL-C/apoA-I, non-HDL-C/apoA-I, and apoB/apoA-I were subsequently included in the multivariate regression model ([Table 2](#jgc-13-08-685-t02){ref-type="table"}), while the rest of lipid and lipoprotein parameters including HDL-C, TG or TG/HDL-C and TG/apoA-I were not included in the model. In Addition, both LVEF and Glycosylated hemoglobinA1C (HbA1C) were with a *P* \< 0.05 in the univariate regression analysis. When adjusted for gender, age, current smoking, hypertension, disperlipidemia and family history of CAD in model 1, parameters including apoB/apoA-I, non-HDL-C, LDL-C/apoA-I, non-HDL-C/apoA-I, and lipoprotein (A) showed relatively significant and strong associations with high GS (OR = 10.33, 8.40, 5.41, 3.35, 2.06, respectively, and all *P* \< 0.05). After further adjustment for LVEF, HbA1C, and statin therapy (before hospitalization) in model 2, the lipoprotein (A), and the ratios including apoB/apoA-I, LDL-C/apoA-I, and non-HDL-C/apoA-I showed the much more powerful and independent predictive value for high GS compared with other lipid and lipoprotein parameters (OR = 5.67, 4.65, 3.42, 1.65, respectively, and all *P* \< 0.05). As a result, the two multivariate logistic analysis models both demonstrated that the apoB/apoA-I was the most powerful predictor for high GS in type 2 DM-CAD patients. In addition, it\'s worth mentioning that the lipoprotein (A), the only one lipid measurement among the lipids and apos parameters, showed a significant association with high GS in each model, and it might be an important predictive factor for the severity of CAD. More interestingly, this predictive value was independent of the apo B/apo A-I (OR: 1.77, 95% CI: 1.04--3.01, *P* = 0.036) (data not shown).

3.3. Correlation analysis and receiver operating characteristic (ROC) curves analysis {#s3c}
-------------------------------------------------------------------------------------

In correlation analysis, natural log-transformed GS (lnGS) was used. All of the lipid and lipoprotein ratios were normal distribution data. Pearson\'s correlation analysis was performed to investigate the correlation of the GS with the lipid and lipoprotein ratios. Positive and significant correlations of the ratios including apoB/apoA-I, non-HDL-C/apoA-I, and LDL-C/apoA-I with lnGS (*r* = 0.18, 0.13, 0.12, respectively, and all *P* \< 0.05; [Figure 1](#jgc-13-08-685-g001){ref-type="fig"}) were detected, but no significant correlation were observed between TG/HDL-C, TG/apoA-I, TC-C/HDL-C, or LDL-C/HDL-C and lnGS ([Figure 1](#jgc-13-08-685-g001){ref-type="fig"}).

In ROC curves analysis, area under the curve (AUC) indicated the well discriminatory power of apoB/apoA-I (AUC = 0.63, 95% CI: 0.60--0.66, and *P* = 0.001) for high GS ([Figure 2](#jgc-13-08-685-g002){ref-type="fig"}). The optimal cutoff value of apoB/apoA-I to predict high GS was 0.72 (with a sensitivity of 61.2% and a specificity of 62.1%).

4. Discussion {#s4}
=============

The main findings of the present study were that: (1) the baseline apoB/apoA-I appeared to be superior to all traditional lipid and lipoprotein parameters in predicting high GS (≥ 47-point) in DM patients with newly diagnosed CAD; (2) there were significantly positive correlations of the ratios including apoB/apoA-I, non-HDL-C/apoA-I, and LDL-C/apoA-I with lnGS (*r* = 0.18, 0.13, 0.12, respectively; and all *P* \< 0.05); (3) the optimal cutoff value of apoB/apoA-I in predicting for high GS in DM patients with CAD was 0.72 (with a sensitivity of 61.2% and a specificity of 62.1%).

###### Clinical characteristics of the study population.

  Variables                              Low GS            Intermediate GS            High GS          *P*^a^   *P*^b^
  ------------------------------ ---------------------- ---------------------- ---------------------- -------- --------
  Risk factors                                                                                                 
   Age, yrs                            59.8 ± 8.8             59.2 ± 9.9             60.7 ± 9.3        0.554    0.312
   Male                                80 (63.0%)             82 (66.1%)             97 (75.2%)        0.182    0.073
   Smoking                             58 (45.7%)             57 (46.0%)             61 (47.3%)        0.951    0.775
   Family history of CAD               18 (14.2%)             20 (16.1%)             23 (17.8%)        0.632    0.365
   BMI, kg/m^2^                        26.6 ± 3.8             25.9 ± 4.2             26.2 ± 3.3        0.223    0.550
   Hypertension                        97 (76.4%)             94 (75.8%)             91 (70.5%)        0.584    0.300
   Dyslipidemia                       112 (88.2%)            103 (83.1%)             97 (75.2%)        0.059    0.032
   PVD                                  2 (1.6%)               3 (2.4%)               3 (2.3%)         0.708    0.641
   Stroke                               4 (3.2%)               3 (2.4%)               4 (3.1%)         0.969    0.896
   Duration of diabetes, yrs           7.8 ± 6.2              8.1 ± 5.5              11.0 ± 6.3        0.022    0.006
   SBP, mmHg                          129.1 ± 18.2           123.5 ± 15.1           124.1 ± 13.9       0.197    0.486
   DBP, mmHg                           77.6 ± 9.8             74.9 ± 8.8             74.9 ± 9.9        0.299    0.465
  Lipid profile                                                                                                
   TG, mg/dL                      147.1 (109.9--225.0)   140.0 (102.8--201.1)   140.0 (104.5--187.8)   0.385    0.413
   TC, mg/dL                          159.6 ± 41.3           157.5 ± 46.1           168.6 ± 46.1       0.182    0.069
   LDL-C, mg/dL                       91.2 ± 31.8            92.9 ± 35.4            104.0 ± 39.7       0.026    0.007
   HDL-C, mg/dL                       41.6 ± 11.0             41.5 ± 9.0             40.0 ± 8.6        0.451    0.206
   Non-HDL-C, mg/dL                   117.8 ± 38.2           115.6 ± 45.2           128.5 ± 43.9       0.079    0.026
   Lipoprotein (A), mg/dL           13.4 (5.9--27.6)       15.6 (4.9--27.4)       19.9 (6.8--45.1)     0.034    0.010
   ApoA-I, mg/dL                     136 (129--165)      142.0 (129.8--155.3)   138.0 (123.0--151.0)   0.185    0.079
   ApoB, mg/dL                        95.9 ± 28.7            97.6 ± 32.5            107.0 ± 32.7       0.028    0.008
  Laboratory test                                                                                              
   Creatinine, µmol/L                 70.4 ± 15.5            73.1 ± 15.7            75.1 ± 15.0        0.096    0.075
   Uric acid, mmol/L                  325.6 ± 93.8           344.5 ± 83.3          350.9 ± 111.9       0.173    0.188
   AST, IU/L                       16.0 (12.0--20.0)         16 (13--22)         15.0 (12.0--18.0)     0.058    0.019
   ALT, IU/L                       22.0 (16.5--31.5)      23.0 (17.0--34.3)      21.0 (15.0--29.0)     0.158    0.055
   HbA1C, %                          7.1 (6.7--7.9)         7.0 (6.4--7.9)         7.4 (6.7--8.3)      0.075    0.036
   NT-pro-BNP, fmol/mL             516 (436.2--636.8)    552.1 (428.0-668.2)    600.2 (451.9--790.9)   0.059    0.019
   LVEF, %                             65.9 ± 5.0             65.7 ± 5.1             64.4 ± 5.8        0.094    0.030
   Hs-CRP, mg/L                      1.9 (1.0--3.1)         1.6 (0.6--3.3)         2.0 (0.9--4.0)      0.406    0.570
  Lipids and lipoprotein ratio                                                                                 
   TG/HDL-C                        3.86 (2.51--5.45)      3.44 (2.41--5.27)      3.58 (2.54--4.84)     0.644    0.724
   TC/HDL-C                            4.0 ± 1.2              3.9 ± 1.3              4.3 ± 1.3         0.055    0.017
   LDL-C/HDL-C                         2.2 ± 0.9              2.3 ± 0.9              2.7 ± 1.0         0.005    0.001
   TG/ApoA-I                       1.08 (0.79--1.46)      0.94 (0.73--1.39)      1.00 (0.72--1.32)     0.624    0.759
   Non-HDL-C/ApoA-I                   0.82 ± 0.28            0.81 ± 0.34            0.92 ± 0.31        0.004    0.006
   LDL-C/ApoA-I                       0.65 ± 0.22            0.64 ± 0.25            0.74 ± 0.27        0.021    0.001
   ApoB/ApoA-I                        0.66 ± 0.20            0.68 ± 0.23            0.77 ± 0.23        0.002    0.001
  Statin therapy                       69 (54.3)              70 (56.5)              67 (51.9)         0.850    0.648

The data shown are the mean ± SD, median (Q1--Q3 quartiles) or *n* (%). ^a^*P* value obtained from analysis of variance, Kruskal-Wallis test, or chi-squared test; ^b^*P* value for high GS *vs*. non-high (low and intermediate), GS obtained from analysis of *t*-test, Mann-Whitney test, or Chi-squared test. ALP: alkaline phosphatase; ALT: alanine aminotransferase; ApoA-I: apolipoprotein A-I; Apo B: apolipoprotein B; AST: aspartate aminotransferase; BMI: body mass index; CAD: coronary artery disease; DBP: diastolic blood pressure; GS: Gensini score; HbA1c: glycosylated hemoglobinA1C; HDL-C: high density lipoprotein cholesterol; hs-CRP: high sensitivity C-reactive protein; LDL-C: low density lipoprotein cholesterol; LVFE: left ventricular ejection fraction; NT-pro-BNP: N-terminal pro-brain natriuretic peptide; PVD: peripheral vascular disease; SBP: systolic blood pressure; TC: total cholesterol; TG: triglycerides.

###### Multivariate logistic regression analysis of detecting independent factors for high GS ( \> 47-point).

  Variables           Model 1     Model 2                                 
  ------------------ --------- ------------- ------- ------ ------------- -------
  LDL-C                1.01     1.00--1.02    0.004   1.01   1.00--1.02    0.048
  Non-HDL-C            8.40     1.51--46.8    0.014   5.42   0.57--51.59   0.142
  ApoB                 1.01     1.00--1.02    0.002   1.01   1.00--1.02    0.091
  Lipoprotein (A)      2.06     1.23--3.47    0.006   1.65   1.04--3.03    0.045
  TC/HDL-C             1.32     1.08--1.62    0.008   1.42   0.72--2.80    0.310
  LDL-C/HDL-C          1.57     1.19--2.06    0.001   1.43   1.03--1.98    0.033
  ApoB/HDL-C           1.62     1.21--2.15    0.001   1.36   0.98--1.91    0.069
  Non-HDL-C/ApoA-1     3.35     1.49--7.51    0.003   3.42   1.21--9.67    0.021
  LDL-C/ApoA-1         5.41     1.98--14.81   0.001   4.65   1.35--15.97   0.015
  ApoB/ApoA-1          10.33    3.04--35.14   0.000   5.67   1.45--23.92   0.018

Abnormal distribution data were analyzed after logarithmic transforming. Model 1: adjusted for gender, age, current smoking, hypertension, hyperlipidemia, family history of CAD; Model 2: as in model 1 further adjusted for LVEF, HbA1C, duration of diabetes, and statin therapy (before hospitalization). ApoA-1: apolipoprotein A-1; ApoB: apolipoprotein B; CAD: coronary artery disease; GS: Gensini score; HbA1C: glycosylated hemoglobinA1C; HDL-C: high density lipoprotein cholesterol; LDL-C: low density lipoprotein cholesterol; LVEF: left ventricular ejection fraction; TC: total cholesterol.

![The correlation of the lipid and lipoprotein ratios with lnGS in type 2 DM.\
Pearson\'s correlation analysis was performed. ApoA-I: apolipoprotein A-I; ApoB: apolipoprotein B; DM: diabetes mellitus; GS: Gensini score; HDL-C: high density lipoprotein cholesterol; LDL-C: low density lipoprotein cholesterol; TC: total cholesterol; TG: triglycerides.](jgc-13-08-685-g001){#jgc-13-08-685-g001}

As we know, GS assessment system has been world-widely used in cardiovascular field. It is a simple and useful tool in evaluating the severity of coronary stenosis and provides an accurate stratification of patients according to the functional significance of their disease.[@b16] In the current study, we chose the GS as an approach for evaluating the severity of the CAD in Chinese patients with T2DM and new on-set CAD.

Concerning the usefulness of the lipid and lipoprotein ratios in predicting CAD, considerable studies had already reported. For example, in a large sample, prospective study, the apoB/apoA-I and the TC/HDL-C was reported to be related to the first major adverse cardiovascular events.[@b17] Schmidt, *et al*.,[@b18] indicated that in initially healthy middle-aged men the apoB/apoA-I was the independent risk factor and the strongest predictor for MI. Sniderman, *et al*.,[@b19] suggested that the apoB/apoA-I was also an independent predictors of future MI in patients with insulin resistance and metabolic syndrome. In another prospective study of US population, Sierra-Johnson, *et al*.,[@b20] showed that both the apoB/apoA-I and the TC/HDL-C were related to CAD death. Furthermore, accumulating evidence had indicated that the apoB/apoA-I was a better marker of cardiovascular events than any of the cholesterol ratios,[@b4],[@b5] although dispute still existed.[@b21],[@b22] Interestingly, the apoB/apoA-I differed across ethnicities, among African Americans, but not in European-American subjects, elevated apoB/apoA-I independently associated with a greater risk of CAD.[@b2] Unfortunately, these studies did not investigate the relation between the lipid and lipoprotein ratios and the severity of coronary atherosclerosis.

![ROC curves analysis.\
ROC curves showed discriminatory power of the lipid and lipoprotein ratios for high GS (≥ 47-point) in type 2 DM. ApoA-I: apolipoprotein A-I; ApoB: apolipoprotein B; AUC: area under the curve; DM: diabetes mellitus; GS: Gensini score; HDL-C: high density lipoprotein cholesterol; LDL-C: low density lipoprotein cholesterol; ROC: receiver-operating characteristic; TC: total cholesterol.](jgc-13-08-685-g002){#jgc-13-08-685-g002}

Until recently, the close relation between the lipid and lipoprotein ratios and the severity of coronary artery stenosis was reported.[@b23],[@b24] Yang, *et al*.,[@b23] indicated in their study that the severity of coronary artery lesions assessed by GS was correlated with abnormal lipid metabolism. Meanwhile, the ratios of LDL-C/HDL-C and TC/HDL-C were better indicators than other lipid parameters. Following this study, Momiyama, *et al*.,[@b24] demonstrated that the LDL-C/HDL-C was associated with the severity of coronary atherosclerosis. Whereas, there were no more lipid and lipoprotein ratios, such as apoB/apoA-I and cholesterol to apoA-I ratios were compared.

It is well acknowledged that type 2 DM is often accompanied with CAD, the long-time survival is significantly reduced in DM-CAD patients when compared with CAD patients without DM.[@b25] Therefore, intensive attention should be paid to the control of CAD risk factors in type 2 DM patients. However, the intensive glycemic control seems not to bring about an improved survival. Of note, patients with type 2 DM have an increased prevalence of lipid and lipoprotein abnormalities contributing to their high risk of CAD.[@b26] As mentioned before, lipid profile in type 2 DM is characterized by an increased TG, apo B level, and a lower HDL-C level.[@b8] Moreover, hypertriglyceridemia is frequently associated with premature cardiovascular disease.[@b27] Accordingly, detecting those lipid-related risk predictors of the severity of CAD in type 2 DM might have a crucial significance.

To our knowledge, no study has explored the relationship between the lipid and lipoprotein ratios and the severity of new on-set CAD in type 2 DM until now. Actually, our previous study has found that apoB/apoA-I ratio was more significantly associated with the extent of coronary artery lesions in T2DM patients with stable CAD by univariate logistic regression analysis and the association disappeared by multivariate analysis.[@b9] Despite this, the participants in our previous study were patients with stable CAD, of whom the ones under pre-percutaneous coronary intervention, pre-coronary artery bypass grafting or post-MI were not excluded. Hence, we further evaluated the association between apoB/apoA-I ratio and the severity of CAD in patients with T2DM and new on-set CAD. In the present study, we found that the apoB/apoA-I was still the best indicator in predicting for high GS of CAD in type 2 DM patients after adjustments for some traditional risk factors of cardiovascular disease. Although some patients were on statins, no significant difference in usage rate of statins was found among the three groups of low, middle and high GS. Furthermore, after adjustment for statins therapy, apoB/apoA-1 was still associated with GS. Moreover, the ratios concerning apoA-I seemed to be superior to all traditional lipid and lipoprotein parameters and other ratios. In the present study, there were positive and significant correlations of the ratios including apoB/apoA-I, LDL-C/apoA-I, and non-HDL-C/apoA-I with lnGS. Regarding to the reasons of the apoB/apoA-I as a superior predictor for the CAD risk, previous studies has reported extensively.[@b2],[@b5],[@b17],[@b28] Firstly, the pathophysiologic bases for the superiority of apoB over LDL-C should be taken into consideration. Secondly, measurement of Apos has methodological advantages over lipids, and the former has international standardization with no need for fasting. Thirdly, apoB level can be measured directly and accurately and the measurement is still reliable for patients with high TG levels (such as that in type 2 DM).[@b29] Therefore, it is noteworthy that the apoB/apoA-I has the powerful predictive value for the severity of new on-set CAD in type 2 DM. Nevertheless, we must to point out that although the apo B/apo A-I appears to predict GS better than other ratios, the additional predictive value over lipid and lipoprotein ratios, e.g., LDL-C/HDL-C was modest. The underlying explanations are still under discussion.

In conclusion, the present study explored the relation between the lipid and lipoprotein ratios, and CAD risk in DM patients and confirmed their values for predicting the severity of CAD. Importantly, our study indicated that the apoB/apoA-I might be the most useful predictor for the severity of CAD in DM patients. Additionally, the values of other lipid and lipoprotein ratios including LDL-C/HDL-C, non HDL-C/apo A1, and LDL-C/apo A1 were also of some clinical importance. These findings might be meaningful to confirm the importance of the lipid and lipoprotein indicators of atherosclerosis and disease progression, and contribute a better predictive outcome or provide an important proxy for treatment protocols in DM patients with CAD.
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